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Background: Polymorphisms of the CC chemokine receptor 6 (CCR6) and RNASET2 tag SNP have been shown to
be associated with the susceptibility to several immune-related diseases. This study was conducted to identify the
association of CCR6 and RNASET2 tag SNP with autoimmune thyroid diseases (AITDs) in the Chinese Han population.
Methods: We enrolled 1061 patients with AITDs, including 701 patients with Graves’ disease (GD) and 360 patients
with Hashimoto’s thyroiditis (HT), and 938 healthy individuals for a case–control genetic association study. Three CCR6
single nucleotides polymorphisms (SNPs) (rs3093023/rs3093024/rs6902119) and one tagging SNP (rs9355610) within
RNASET2 gene were selected for genotyping by multiplex polymerase chain reaction (PCR) and ligase detection
reaction (LDR).
Results: The frequency of rs9355610 genotypes in the patients with GD differed significantly from that in the controls
(p = 0.017). The frequency of the minor G allele of rs9355610 was significantly higher in the GD patients than in the
healthy controls (p = 0.005, OR = 1.225, 95% CI:1.063-1.412). However, we could not find significant differences in the
genotype or allele frequencies of HT patients compared with healthy controls. After gender stratification, the frequency
of the minor G allele in both male and female GD patients was significantly higher than that in the healthy controls
(p = 0.036, OR = 1.308, 95% CI:1.017-1.684 ; p = 0.048, OR = 1.19, 95% CI:1.001-1.413; respectively);. Furthermore, the
frequency of haplotype AT in GD patients was significantly lower than that in their control groups (p = 0.003) and
showed a protective effect against GD (OR = 0.806, 95% CI: 0.699-0.929). The frequency of haplotype GT in GD patients
was significantly higher than that in their control groups (p = 0.048), indicating that GT was the risk haplotype to GD
(OR = 1.267, 95% CI: 1.001-1.603). There were no significant differences in the allele or genotype frequencies of three
SNPs of CCR6 (rs3093023/rs3093024/ rs6902119) gene between GD patients, HT patients and controls.
Conclusions: Our results suggest that the rs9355610 tag SNP of RNASET2 gene is positively associated with
susceptibility to GD in the Chinese Han population. No association was found for the tested CCR6 SNPs.
Keywords: RNASET2, CCR6, Single nucleotide polymorphisms (SNPs), Autoimmune thyroid diseases (AITDs), Graves’
disease (GD), Hashimoto’s thyroiditis (HT)Background
Autoimmune thyroid disease (AITD) is an organ-specific
autoimmune disease characterized by the break-down of
self-tolerance to thyroid antigens and the occurrence in
the serum of antibodies against thyroid self-antigens. Two
typical AITDs, Graves’ disease (GD) and Hashimoto’s* Correspondence: zhangjinan@hotmail.com
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unless otherwise stated.thyroiditis (HT), affect up to 5% of the general population
[1], and both of are characterized pathologically by infil-
tration of the thyroid by T and B-cells reactive to thyroid
antigens, biochemically by the production of thyroid auto-
antibodies, and clinically by abnormal thyroid functions
(hyperthyroidism in GD and hypothyroidism in HT) [2].
The current paradigm is that AITDs are complex dis-
eases in which susceptibility genes and environmental
triggers act in concert to initiate the autoimmune
response to the thyroid. While the exact etiology ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for a strong genetic influence on the development of
AITD. The putative GD and HT susceptibility genes
include both immune modifying genes HLA Class II
gene [3,4], cytotoxic T lymphocyte-associated factor 4
(CTLA-4) gene [5,6], CD40 gene [5-7], protein tyrosine
phosphatase-22 (PTPN22) gene [5], and other thyroid-
specific genes for the thyroid stimulating hormone receptor
(TSHR) [5,8] and thyroglobulin (TG) [9], as well as the
novel proinflammatory cytokine such as interleukin-17
(IL-17) [10] and IL-21 [11]. All these data suggest that
genetic factors may play an important role in the patho-
genesis of AITD.
CC chemokine receptor 6 (CCR6), a member of the β
chemokine receptor family, is expressed in immature
dendritic cells, memory T cells, lymphocytes and B cells
[12-14]. The CCR6 gene encodes C-C motif chemokine
receptor 6, the receptor for CCL20 and a surface marker
for IL-17–producing T helper 17 (Th17) cells [13]. It
is believed that CCL20/CCR6 signaling plays a role in
the recruitment of not only immature dendritic cells
and their precursors, but also Th17 cells, into sites of
potential antigen entry [13]. The pathogenesis of vari-
ous autoimmune diseases and inflammatory diseases
has been linked to the involvement of Th17 cells, most
of them reporting CCR6 as a key factor for involvement
of Th17 cells [15-17]. We also have reported that IL-17
might play an key pole in the pathogenesis of HT and
IL-17A/F polymorphisms may affect the susceptibility
to AITD [10,18]. Recent studies have suggested that
CCR6 polymorphisms are associated with an increased
risk for a variety of autoimmune- or immune-mediated
diseases, such as rheumatoid arthritis (RA) [19,20],
Crohn’s disease [21], systemic sclerosis (SSc) [22] and
vitiligo [23]. However, it remains unknown whether
CCR6 polymorphisms are associated with AITD in the
Chinese population which was the subject of this
study.
Chu et al. carried out a genome-wide association study
(GWAS) of individuals with GD in a Chinese Han popula-
tion and identified novel GD susceptibility loci rs9355610,
within 6q27 chromosomal bands that contribute to gener-
alized GD risk [24]. Of interest is the fact that HT is also
the clinical subtype of AITDs and shares the similar gen-
etic predisposition with GD. Whether genes in this region
are also associated with HT is unknown and is therefore
the subject of this study.
In this study, we therefore conducted a large case–
control study to determine the genetic association of the
selected SNP of CCR6(rs3093023/rs3093024/rs6902119)
and one tagging SNP (rs9355610) within RNASET2 with
AITD in a cohort of the Chinese Han population.
Furthermore, we analyzed the association between geno-
types and AITD clinical characteristics.Methods
Study population
The study population (n = 1999) consisted of 1061 Chinese
Han non-related AITD patients including 701 patients with
GD and 360 patients with HT; and 938 unrelated, ethnically
matched healthy controls. All AITDs patients were enrolled
from the Outpatient Department and Inpatient Department
of Endocrinology of Jinshan Hospital of Fudan University;
ethnically and geographically matched healthy controls
were recruited from the Health Check-Up Center of the
hospital. The subjects were all of self-reported Chinese Han
ethnicity. This study was approved by the Ethics Committee
of Jinshan Hospital of Fudan University. Written informed
consent was obtained from all subjects. All procedures
followed the tenets of the Declaration of Helsinki.
Inclusion criteria: AITDs patients were diagnosed as
described in our published papers [25]. GD was diagnosed
based on clinical and laboratory biochemical evidence of
hyperthyroidism by the presence of diffuse goiter, and sup-
ported by the positive anti-thyroid stimulating hormone
receptor antibody (TRAb) and/or anti-thyroid peroxidase
antibody(TPO-Ab) and/or anti-thyroglobulin(Tg-Ab) and/
or exophthalmos. HT was diagnosed based on the pres-
ence of an enlarged thyroid and either TPO-Ab or Tg-Ab,
with or without documented clinical and biochemical
hypothyroidism. For the suspicious cases of HT, diagnoses
were confirmed by fine needle aspiration biopsies (FNAB).
Exclusion criteria: All healthy subjects without clinical
evidence (goiter, TPOAb, and TGAb) and family history
of thyroid diseases and any other autoimmune diseases.
The clinical manifestations of AITD patients include:
(1) adult- or childhood- onset AITDs, according to the
age of disease onset (≤18 years versus ≥19 years); (2)
presence or absence of ophthalmopathy in GD group
(defined as a distinctive disorder characterized by inflam-
mation and swelling of the extraocular muscles, eyelid
retraction, periorbital edema, episcleral vascular injection,
conjunctive swelling and proptosis); (3) presence or ab-
sence of thyroid dysfunction in HTgroup: euthyroid status
or hypothyroidism; and (4) presence or absence of AITDs
family history.
DNA extraction and genotyping
From all the study participants, peripheral venous blood
of 2 mL was collected and genomic DNA was extracted
from peripheral blood cells using the Nucleon Bacc kit
(TianGen Biotech Co., Ltd., Beijing, China), according
to the manufactures’ guidelines. Four selected SNPs
(rs3093023/rs3093024/rs6902119/rs9355610) were geno-
typed by ligase detection reactions (LDR) platform in
Shanghai Biowing Applied Biotechnology Company
(http://www.biowing.com.cn/). This is a well-established
platform used by many researchers for studies including
SNP genotyping [25]. The target DNA sequences were
Table 1 The demographic and clinical characteristics of
the AITDs patients and the controls
Characteristics GD patients






Male (%) 214(30.5) 44(12.2) 309(32.9)
Female (%) 487(69.5) 316(87.8) 629(67.1)
Age (mean ± SD) 36.86 ± 14.549 35.09 ± 13.786 38.61 ± 9.202
Age of onset 33.98 ± 14.344 32.79 ± 13.465 -
≤18 years 113(16.12) 51(14.2) -
≥19 years 588(83.88) 309(85.8) -
Thyroid size -
Normal size (%) 22(3.1) 12(3.3) -
Degree I (%) 127(18.1) 59(16.4) -
Degree II (%) 425(60.7) 253(70.3) -
Degree III (%) 127(18.1) 36(10.0) -
Family history (%) 174(24.8) 79(21.9)
Ophthalmopathy (%) 135(19.3) 9(2.5) -
Thyroid antibodies -
TPOAb 398(56.7) 252(70.0) -
TgAb 303(43.2) 226(62.8) -
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Extracted DNA was amplified by PCR using the Gen-
eAmp PCR System 9600 (Perkin Elmer, Waltham, MA,
USA) for PCR amplification. The reaction course included
initial denaturation at 95°C for 2 min, denaturation at 94°C
for 30 s, annealing at 56°C for 1 min, extension at 65°C for
30 s with 35 cycles, and final extension at 65°C for 10 min.
After the reaction, 2μL of each product was run in a 3.0%
agarose gel to determine whether the reaction had been
successful. After the completion of the amplification, the
ligation detection reaction for each subject was carried
out in a final volume of 10 μl containing 1 μL buffer (1×),
1 μL Prob mix (2 pmol/μL), 1 μL of Multi-PCR product
(100 ng/μL), 6.95 μL H2O, 0.05 μL of 2 U/μL Taq DNA
ligase (New England Biolabs, Ipswich, MA, USA). The
LDR was performed using 40 cycles of denaturation at
95°C for 2 min, annealing at 94°C for 15 s and extension
at 50°C for 25 s. The LDR fluorescent product was ana-
lyzed using an ABI sequencer 377 (Applied Biosystems),
and the results were analyzed with Genemapper software.
In addition to ensuring quality of the assay, we made
double positive controls (duplication of the same DNA
samples) and negative controls (blank samples without
DNA) in the processor of SNP genotyping. Quality con-
trol analysis was also performed so that only SNPs and
samples which had passed the 95% quality control
threshold were subjected to further statistical analysis.
Statistical analysis
Statistical analyses were performed using SPSS version 17.0
software (SPSS Inc., Chicago, IL, USA). Each genetic marker
was tested for Hardy-Weinberg equilibrium in the control
population using the HWE program (http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl). A linkage disequilibrium (LD) map used to
define the haplotype blocks was constructed using Haploview
software (version 4.2; http://www.broadinstitute.org/haplo
view/haploview). The haplotype analysis was performed to
compare distributions of haplotype frequencies of SNPs
between cases and controls. All the allele and genotype
frequencies between the patients and the controls wereassessed by χ2-test. The two-tailed independent samples t
test was performed to evaluate the diversity of parameters
between groups of different genotypes. To examine
whether each SNP independently contributes to suscepti-
bility to AITD, conditional logistic regression analysis was
employed. All tests were two-tailed, considering p-values
<0.05 as significant. Odds ratios were calculated for the
minor allele at each SNP.
Power calculation
The power of the data was assessed using the Power and
Sample Size Calculation software (Ps; version 3.0; http://
biostat.mc.vanderbilt.edu) [26]. Taking into account the
expected frequency of the CCR6 rs9355610 minor allele
(46.1%) in the general population, the combined set of
1061 AITD cases and 938 controls provided a power of
81.7% to detect an association between AITD and these
variants, with an OR of 1.2 at the 5% significance level.
Results
Clinical characteristics of the subjects
To investigate whether four selected SNPs contribute to
the susceptibility to AITD, we performed a case and
control association study. As shown in Table 1, in the GD
patients 69.5% were females, the mean age was 36.86
years; in the HT patients 87.8% were females, the mean
age was 35.09 years. In the healthy controls, 67.1% individ-
uals were females and the overall mean age was 38.61
years. There was no difference in age distribution between
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AITD patients are also presented in Table 1.
Association of rs3093023/rs3093024/rs6902119/rs9355610
polymorphisms with susceptibility to AITD
The distribution of genotype frequencies of each SNP in
both the patients and the controls were in Hardy-Weinberg
equilibrium (p > 0.05).
Differences in genotypic and allelic frequencies of SNPs
between the patients and the controls were compared and
are presented in Table 2. There were no significant differ-
ences in the allele or genotype frequencies of three SNPs
of CCR6 (rs3093023, rs3093024, rs6902119) between
AITD patients, GD patients, HT patients and controls.
However, rs9355610 appeared to be associated with AITD
susceptibility. The frequencies of rs9355610 genotypes in
patients with GD (GG, 25.3%; AG, 51.7% and AA, 23.0%)
differed significantly from those in the controls (GG,
30.0%; AG, 50.3% and AA, 19.7%) (p = 0.017). We ob-
served a significant increase in the frequency of the minor
G allele of rs9355610 in the AITD and GD patients com-
pared with that in healthy controls and seemed to have
higher risks for AITD and GD (in AITD: 49.9% vs.46.1%;
p = 0.018, OR = 1.166, 95% CI = 1.026-1.324; in GD:51.2%
vs. 46.1%; p = 0.005, OR = 1.225, 95% CI = 1.063-1.412).Table 2 Genotype and allele distribution of CCR 6- RNASET2 ge
SNP Allele/ Pa
Genotype Controls AITD (OR, 95% CI)
rs3093023 GG 329(36.9) 341(33.4) 0.252
AG 423(47.5) 507(49.6)
AA 139(15.6) 174(17.0)
A 701(39.3) 855(41.8) 0.118
G 1081(60.7) 1189(58.2)
rs3093024 GG 328(36.9) 341(33.4) 0.264
AG 422(47.5) 506(49.6)
AA 139(15.6) 174(17.0)
A 700(39.4) 854(41.8) 0.124
G 1078(60.6) 1188(58.2)
rs6902119 TT 344(38.7) 373(36.5) 0.468
CT 420(47.2) 487(47.7)
CC 126(14.1) 162(15.8)
C 672(37.8) 811(39.7) 0.223
T 1108(62.2) 1233(60.3)
rs9355610 GG 187(30.0) 248(24.2) 0.058
AG 448(50.3) 520(51.1)
AA 256(19.7) 249(24.7)
G 822(46.1) 1016(49.9) 0.018
1.166(1.026-1.3A 960(53.9) 1018(50.1)
Pa value, AITD versus Controls; Pb value, GD versus Controls; Pc value, HT versus ConHowever, we could not find significant differences in the
genotype or allele frequencies of HT patients compared
with those of healthy controls.
After gender stratification (shown in Table 3), the fre-
quency of the minor G allele of rs9355610 in both male
and female GD patients was significantly higher than that
in the healthy controls (p = 0.036, 0.048; respectively); but
the degree of risk for GD was higher in male group than
in female group (OR =1.308, 95% CI: 1.017-1.684 in males;
OR = 1.19,95% CI = 1.001-1.413 in females); the genotype
and the minor G allele distribution of rs9355610 did not
reveal any significant association with HT.
To examine the contribution of each SNP to susceptibil-
ity to AITD, conditional logistic regression analysis was
conducted. As shown in Table 4, the association of
rs9355610 remained significant after adjustment for
rs6902119 SNP genotypes. Adjusted P values (P adjusted)
for rs9355610 under the dominant model were 0.024 after
adjustment for rs6902119. The results suggest that
rs9355610 SNP is independently associated with GD.
Haplotype analysis
Linkage analysis of the four tested SNPs in the controls
showed moderate to strong linkage disequilibrium (Table 5).
To further identify whether haplotypes of those 4 SNPsne in AITDs patients, GD patients, HT patients, and controls
Pb Pc
GD (OR, 95% CI) HT (OR, 95% CI)
224(33.3) 0.242 117(33.4) 0.428
327(48.7) 180(51.4)
121(18.0) 53(15.2)
569(42.3) 0.091 286(40.9) 0.486
775(57.7) 414(59.1)
224(33.4) 0.253 117(33.4) 0.430
326(48.6) 180(51.4)
121(18.0) 53(15.2)
568(42.3) 0.096 286(40.9) 0496
774(57.7) 414(59.1)
233(34.7) 0.183 140(40.0) 0.888
327(48.7) 160(45.7)
112(16.6) 50(14.3)
551(41.0) 0.066 260(37.1) 0.778
793(59.0) 440(62.9)
169(25.3) 0.017 79(22.6) 0.799
345(51.7) 175(50.0)
153(23.0) 96(27.4)
683(51.2) 0.005 333(47.6) 0.516
24) 1.225(1.063-1.412)651(48.8) 367(52.4)
trols; OR, odd ratio; 95% CI, 95% confidence intervals.
Table 3 Analysis of genotype and allele distribution of rs9355610 SNP in the GD patients and the controls after
gender stratification
SNP Alleles/ Controls GD HT Pa Pb
OR (95% CI) OR (95% CI)
Genotypes M (n = 298) F (n = 593) M (n = 205) F (n = 462) M (n = 43) F (n = 307) M F M F
rs9355610 GG 63(21.1) 124(20.9) 56(27.3) 113(24.5) 8(18.6) 71(23.1) 0.110 0.124 0.741 0.675
AG 148(49.7) 300(50.6) 104(50.7) 241(52.2) 20(46.5) 155(50.5)
AA 87(29.2) 169(28.5) 45(22.0) 108(23.3) 15(34.9) 81(26.4)
G 274(45.9) 548(46.2) 216(52.7) 467(50.5) 36(41.9) 297(48.4) 0.036 0.048 0.474 0.383
1.308 1.19
A 322(54.1) 638(53.8) 194(47.3) 457(49.5) 50(58.1) 317(51.6) 1.017-1.684 1.001-1.413 - -
M, male; F, female; Pa value, GD versus Controls; Pb value, HT versus Controls; OR, odd ratio; 95% CI, 95% confidence intervals.
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analyzed haplotype frequency differences between the
AITD patients and the controls. Two detected LD blocks
shown in Figure 1 are rs9355610-rs6902119, rs3093023-
rs3093024. Table 6 shows the frequency of haplotype
AT in AITD and GD patients were significantly lower
than that in their control groups (p = 0.016, 0.003),the
AT haplotype showed a protective effect on AITD and
GD (OR = 0.856,95% CI = 0.754-0.972; OR = 0.806, 95%
CI = 0.699-0.929); the frequency of haplotype GT in AITD
and GD patients were significantly higher than that in
their control groups (p = 0.045, 0.048; respectively), indi-
cating that GT was the risk haplotype to AITD and
GD (OR = 1.245, 95% CI = 1.005-1.541; OR = 1.267,
95% CI = 1.001-1.603). However, the haplotypes of block 2
were neither associated with GD nor with HT.
Genotype and clinical phenotype correlations
We also conducted a study on the effects of clinical pa-
rameters, including family history, age of onset (≤18Table 4 Interaction analysis of gene-gene in AITD, GD and HT
Codominant model
SNP rs3093024 rs69










rs3093023 0.668 0.966 0.191 0.51
rs3093024
rs6902119
*The data are presented as Padjusted values (AITD/ GD/ HT) from a multiplicative inteyears or ≥ 19 years), ophthalmopathy in GD patients, in-
tractable GD or GD in remission and thyroid dysfunction
in HT patients (Hypothyroidism or normal), on the asso-
ciation of the tested four SNPs with AITD. Unfortunately,
the results demonstrated no detectable association of
these parameters with these SNPs (data not shown).
Discussion
CCR6 encodes a receptor for macrophage inflammatory
protein-3a (CCL20) that is expressed in unactivated
memory B and T cells, Th17 cells and some dendritic
cells and that plays a key role in B-cell differentiation
and tissue-specific migration of dendritic and T cells
during inflammatory and immunological responses [27].
A number of autoimmune diseases may share similar
gene susceptibility and previous studies have reported
significant associations between genetic polymorphisms
of CCR6 and certain autoimmune diseases such as RA,
Crohn’s disease, SSc and vitiligo [19-23]. In this study, we
investigated whether polymorphisms of CCR6 includingpatients, by logistic regression*
02119 rs9355610
2 0.886 0.447 0.821 0.353 0.391
0.941 0.492 0.441
1.0 0.09 0.738 0.874 0.157
1.0
0.370 0.024 0.181
4 0.287 0.999 0.391 0.432 0.101
0.999
0.679 0.937 0.769
raction model. The regression models were adjusted for age and sex.
Table 5 Linkage disequilibrium in controls
L1 L2 D' r^2
Controls Controls
rs9355610 rs6902119 0.97 0.668
rs9355610 rs3093024 0.727 0.402
rs9355610 rs3093023 0.724 0.400
rs6902119 rs3093024 0.819 0.625
rs6902119 rs3093023 0.817 0.621
rs3093024 rs3093023 1.000 0.998
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tagSNP rs9355610 contributed to development of AITD
in Chinese Han case–control cohorts. To our knowledge,
the present study, which analyzed data from a large popu-
lation of Chinese Han subjects, was the first to demon-
strate an association between CCR6 polymorphisms and
susceptibility to AITD in the Chinese Han population.
Our results showed no association of three SNPs out of
the four tested SNPs, i.e. rs3093023, rs3093024 and
rs6902119 in the CCR6 gene, with AITD; however, the
minor G allele of rs9355610 was significantly associated
with susceptibility to GD.
With regard to the selection of the three SNPs of
CCR6, the strategy was principally based on the papersFigure 1 Linkage disequilibrium (LD) block defined by the
Haploview 4.2.reported recently, which are mainly about CCR6 poly-
morphisms with RA and other autoimmune diseases
using candidate gene approaches and genome-wide
association studies (GWAS) [19,20]. Recent GWAS have
identified SNPs in the 6q27 region associated with RA
(rs3093024 and rs3093023 near CCR6) [19,20] and vitiligo
(rs6902119 near CCR6) [28]. Rs3093023/rs3093024 have
been proved to be as the new risk locis for RA in different
ethnic groups, including Japanese [20], Singaporeans [29]
and Europeans [19]; rs6902119 has been identified as risk
loci for vitiligo in Japanese [28]. Unexpectedly, researchers
did not detect any significant associations in the Chinese
Han population between rs3093023/rs3093024/rs6902119
and Vogt-Koyanagi-Harada Syndrome, a well known auto-
immune disease involving the eye, the neurologic/auditory
and integument organs [30]. In the association study on
CCR6 SNPs (rs3093023/rs3093024/rs6902119) with sus-
ceptibility to Behcet’s disease, no association was found
in the Chinese Han population, either [31]. To our
knowledge, there has been no association study on CCR6
SNPs (rs3093023/rs3093024/rs6902119) with AITD in the
Chinese population. Our present study showed no signifi-
cant associations between three tested SNPs of CCR6
and AITD patients in the Chinese population (p > 0.05),
which was consistent with that of the above association
study reported in Vogt-Koyanagi-Harada Syndrome and
Behcet’s disease in the Chinese han population. The
absence of an association in our study is contrary to the
results reported in other autoimmune diseases including
RA, SSc and vitiligo in European and Asian populations
[19-23,28,29]. This might be explained by the fact that
the etiology and pathogenesis of AITD is different from
that of the other autoimmune diseases. Another possibility
could be that Chinese Han people have a genetic back-
ground different from that of other ethnic populations.
Recently Chu et al. [24] has conducted a two-stage
GWAS within the Chinese Han population and identified
rs9355610 as the novel GD susceptibility locus within
6q27 chromosomal near CCR6 gene. The rs9355610 is
located in a block spanning the 5’ exons of RNASET2 and
the intergenic region in the Chinese population. It is
found that the risk allele G of rs9355610 is significantly
associated with reduced mRNA level of RNASET2 only
in CD4+ and CD8+ T cells isolated from 106 healthy
Chinese (p = 6.42 × 10−11and p = 2.00 × 10−7, respectively)
[24]. RNASET2 is the only RNase T2 family member in
humans; the study showed that omega-1, an RNase T2
family member secreted from the eggs of Schistosoma
mansoni, plays a role in priming human dendritic cells
for Th2 polarization of CD4+ T cells [32], indicating that
human RNASET2 might be involved in immune response
and therefore underlie the pathogenesis of GD.
A study carried out in the Polish Caucasian population
with 560 GD patients and 1475 unrelated healthy
Table 6 Haplotype analysis of AITDs patients and controls
Haplotype Controls
(Frequency)
AITD P OR (95% CI) GD (Frequency) P OR (95% CI) HT (Frequency) P OR (95% CI)
Block 1
AT 952(53.3) 1010(49.4) 0.016 0.856 644(47.9) 0.003 0.806 (0.699-0.929) 366(52.2) 0.626 -
0.754-0.972
GC 663(37.2) 795(38.9) 0.265 - 536(39.9) 0.116 - 259(37.0) 0.955 -
GT 160(8.9) 223(11.0) 0.045 1.245 149(11.1) 0.048 1.267 (1.001-1.603) 74(10.6) 0.215 -
1.005-1.541
Block 2
GG 1079(60.5) 1188(58.2) 0.136 774(57.7) 0.105 - 414(59.1) 0.519 -
AA 703(39.5) 854(41.8) 0.136 568(42.3) 0.105 - 286(40.9) 0.519 -
AITDs, autoimmune thyroid diseases; GD, Graves’ disease; HT, Hashimoto’s thyroiditis; OR, odds ratio; CI, confidence interval.
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ciation of allelic frequency distribution of rs9355610
between GD and controls (p = 0.082) [33]. In our present
study, we found that the G allele of rs9355610 signifi-
cantly increased the risk of GD (p = 0.005, OR = 1.225),
but did not associate with HT. This result is consistent
with that of the report on 457 Japanese AITD patients
and 222 matched healthy controls which found that the
SNPs rs9355610 was significantly associated with GD
(p = 0.047), the G allele of rs9355610 was higher in GD
patients than in controls (p =0.0055, OR = 1.42), and
the GG genotype was also significantly increased in GD
patients compared with that in the controls (p = 0.026,
OR = 1.63). All these evidently indicated that the TT
genotype could increase susceptibility to GD; neverthe-
less, there was no association between rs9355610 and
HT [34].
Because analysis of haplotype provides the genetic
information of multiple SNPs, this is a powerful method
for the identification of genes contributing to complex
diseases. In our study, the associated haplotype was in
the same LD block. The rate of AT haplotype was lower
in GD, suggesting a protective effect on GD, while the
rate of the haplotype GT was higher, indicating a signifi-
cant risk factor for GT. This consistency with allele
analysis strongly confirms that G allele of rs9355610 was
a predisposing factor for AITD.
It is worthwhile to point out that several limitations
exist in our study. Although
The association with the RNASET2 gene suggests that
G allele affect expression of RNASET2 gene in CD4+
and CD8+ T cell, we did not perform biological function
tests in control carriers of the various phenotypes.
Because of limited SNPs included in our study, future
study using the high-throughput analytic methods avail-
able (i.e., gene sequencing) may help clarify our findings
and provide further insight into the role of CCR6 in
AITD.Conclusions
This study indicates that the G allele of the RNASET2
tag SNP rs9355610, but not rs3093023, rs3093024 or
rs6902119 in the CCR6 gene, is associated with suscepti-
bility to GD in the Chinese Han population.
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